ARIPIPRAZOLE Drug Patent Profile

Which patents cover Aripiprazole, and what generic alternatives are available?

Aripiprazole is a drug marketed by Mylan, Amneal Pharms, Apotex, Aurobindo Pharma Ltd, Chartwell Rx, Hetero Labs Ltd Iii, Lannett Co Inc, Quagen, Rubicon Research, Vistapharm Llc, Alembic, Orbion Pharms, Sciegen Pharms, Square Pharms, Accord Hlthcare, Aiping Pharm Inc, Ajanta Pharma Ltd, Alkem Labs Ltd, Aurobindo Pharma, Hetero Labs Ltd V, Lupin, Macleods Pharms Ltd, Prinston Inc, Rising, Sunshine, Teva Pharms Usa, Torrent, Unichem, and Zydus Pharms. and is included in thirty-six NDAs.

The generic ingredient in ARIPIPRAZOLE is aripiprazole. There are forty-nine drug master file entries for this compound. Forty-eight suppliers are listed for this compound. Additional details are available on the aripiprazole profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Aripiprazole

A generic version of ARIPIPRAZOLE was approved as aripiprazole by ALEMBIC on April 28^th, 2015.

Summary for ARIPIPRAZOLE

US Patents:	0
Applicants:	29
NDAs:	36
Finished Product Suppliers / Packagers:	45
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	398
Patent Applications:	5,225
Drug Prices:	Drug price information for ARIPIPRAZOLE
Drug Sales Revenues:	Drug sales revenues for ARIPIPRAZOLE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ARIPIPRAZOLE
DailyMed Link:	ARIPIPRAZOLE at DailyMed

See drug prices for ARIPIPRAZOLE

See drug sales revenues for ARIPIPRAZOLE

Recent Clinical Trials for ARIPIPRAZOLE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University Hospital, Strasbourg, France	PHASE2
University of Washington	PHASE1
National Institute on Deafness and Other Communication Disorders (NIDCD)	PHASE1

See all ARIPIPRAZOLE clinical trials

Pharmacology for ARIPIPRAZOLE

Drug Class

Atypical Antipsychotic

Medical Subject Heading (MeSH) Categories for ARIPIPRAZOLE

Antipsychotic Agents

Anatomical Therapeutic Chemical (ATC) Classes for ARIPIPRAZOLE

N05AX	Other antipsychotics
N05A	ANTIPSYCHOTICS
N05	PSYCHOLEPTICS
N	Nervous system

Paragraph IV (Patent) Challenges for ARIPIPRAZOLE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ABILIFY MAINTENA KIT	Extended-release Injectable Suspension	aripiprazole	300 mg/vial and 400 mg/vial	202971	1	2021-12-20
ABILIFY	Oral Solution	aripiprazole	1 mg/mL	021713	1	2007-12-20
ABILIFY	Tablets	aripiprazole	2 mg, 5 mg, 10 mg, 15 mg, 20 mg and 30 mg	021436	8	2006-11-15
ABILIFY	Orally Disintegrating Tablets	aripiprazole	10 mg, 15 mg, 20 mg and 30 mg	021729	1	2006-11-15

US Patents and Regulatory Information for ARIPIPRAZOLE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hetero Labs Ltd V	ARIPIPRAZOLE	aripiprazole	TABLET;ORAL	205064-003	Apr 28, 2015	AB	RX	No	No
Rising	ARIPIPRAZOLE	aripiprazole	TABLET;ORAL	206240-002	Sep 19, 2018		DISCN	No	No
Alembic	ARIPIPRAZOLE	aripiprazole	TABLET;ORAL	202101-002	Apr 28, 2015	AB	RX	No	No
Aiping Pharm Inc	ARIPIPRAZOLE	aripiprazole	TABLET;ORAL	091279-005	Jan 9, 2017		DISCN	No	No
Macleods Pharms Ltd	ARIPIPRAZOLE	aripiprazole	TABLET;ORAL	204111-005	Oct 7, 2016	AB	RX	No	No
Sunshine	ARIPIPRAZOLE	aripiprazole	TABLET;ORAL	213037-003	Oct 2, 2023	AB	RX	No	No
Alkem Labs Ltd	ARIPIPRAZOLE	aripiprazole	TABLET;ORAL	207105-004	Feb 21, 2019	AB	RX	No	No

EU/EMA Drug Approvals for ARIPIPRAZOLE

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Mylan Pharmaceuticals Limited	Aripiprazole Mylan Pharma (previously Aripiprazole Pharmathen)	aripiprazole	EMEA/H/C/003803Aripiprazole Mylan Pharma is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older.Aripiprazole Mylan Pharma is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.Aripiprazole Mylan Pharma is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older.	Authorised	yes	no	no	2015-06-30
Otsuka Pharmaceutical Netherlands B.V.	Abilify	aripiprazole	EMEA/H/C/000471Abilify is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older.Abilify is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.Abilify is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older.	Authorised	no	no	no	2004-06-04
Otsuka Pharmaceutical Netherlands B.V.	Abilify Maintena	aripiprazole	EMEA/H/C/002755Maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole.	Authorised	no	no	no	2013-11-14
Accord Healthcare S.L.U.	Aripiprazole Accord	aripiprazole	EMEA/H/C/004021Aripiprazole Accord is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older., , Aripiprazole Accord is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment., , Aripiprazole Accord is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older.,	Authorised	yes	no	no	2015-11-15
Zentiva, k.s.	Aripiprazole Zentiva	aripiprazole	EMEA/H/C/003899Aripiprazole Zentiva is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older.Aripiprazole Zentiva is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.Aripiprazole Zentiva is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older.	Authorised	yes	no	no	2015-06-25
Sandoz GmbH	Aripiprazole Sandoz	aripiprazole	EMEA/H/C/004008Aripiprazole Sandoz is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older., , Aripiprazole Sandoz is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment., , Aripiprazole Sandoz is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older.,	Authorised	yes	no	no	2015-08-20

Market Dynamics and Financial Trajectory for Aripiprazole

Last updated: March 4, 2026

What Are the Key Factors Driving the Market for Aripiprazole?

Aripiprazole is a second-generation antipsychotic primarily used to treat schizophrenia, bipolar disorder, and as an adjunct for major depressive disorder. Its market growth hinges on several factors:

• FDA Approvals and Label Extensions: Aripiprazole received FDA approval for multiple indications, including schizophrenia and bipolar disorder, expanding its potential market. Notably, the drug was approved for pediatric use in multiple age groups over the years [1].

• Market Penetration and New Formulations: The introduction of long-acting injectable (LAI) formulations, like Abilify Maintena and Aristada, has increased adherence, thereby expanding prescription volume. The LAI formulations accounted for approximately 20% of total aripiprazole prescriptions in 2022.

• Competitive Landscape: Generic versions entered the market after patent expiry in 2015; however, brand-name sales persist due to physician and patient familiarity and preferred dosing options.

• Rising Prevalence of Target Disorders: The global prevalence of schizophrenia is around 1 in 300 persons, with bipolar disorder affecting approximately 1% of the population [2][3]. Increased diagnosis rates may contribute to revenue upticks.

• Off-Label Use and Expansion into New Indications: Use in irritability associated with autism spectrum disorder has been approved in some regions, potentially expanding the market further.

How Does Patent Status and Competition Affect Revenue?

Patent expiration in 2015 led to the proliferation of generic aripiprazole products. While generics lower the cost and increase access, they erode brand-name revenues.

Year	Patent Expiry	Market Impact	Comments
2015	US patent	Introduction of generic versions	Sales declined, but brand maintained loyalty
2018	EU patent	Generic competition increased	Market share dispersed to generics

The original patent portfolio was owned by Otsuka Pharmaceutical and Bristol-Myers Squibb, with listings including composition-of-matter and method-of-use patents. Only the composition patent protected the drug in the immediate post-expiry period; subsequent patent lifespans were limited.

What Are the Financial Trends for Aripiprazole?

Annual sales of branded aripiprazole products peaked at approximately $7.5 billion globally in 2014. Post-patent expiry, total market sales shifted toward the $4 billion range, with generics comprising a majority of prescriptions.

Year	Global Sales (USD billion)	Branded share	Generic share
2014	7.5	80%	20%
2018	4.3	45%	55%
2022	4.0	35%	65%

The decline in branded sales reflects patent expiration and generic competition; however, revenue sustainability relies on the launch of new formulations and expanded indications.

Long-Acting Injectable (LAI) Formulations

LAI products like Abilify Maintena generated approximately $600 million globally in 2022, representing about 15% of total aripiprazole sales. They appeal to patients requiring long-term adherence.

Market Forecast

Analysts project the aripiprazole market to stabilize around $4.2 billion in 2027, driven by:

• Continued generic penetration
• Growth in off-label indications
• Increased adoption of LAI formulations

What Are the Potential Risks and Opportunities?

Risks:

• Patent litigation or new patent filings that could extend exclusivity.
• Competition from emerging antipsychotics with improved safety profiles.
• Off-label use restrictions in certain jurisdictions.

Opportunities:

• Development of biosimilars or biobetters targeting the same indications.
• Expansion into new markets, especially in emerging economies.
• Further innovation in delivery systems or combination therapies.

Key Takeaways

• Patent expiry in 2015 shifted revenues from brand-name to generic products.
• Long-acting injectables have sustained growth in adherence-focused patient segments.
• The market faces ongoing pressure from generics, but expanded indications and formulations offer revenue opportunities.
• Revenue in 2022 approximated $4 billion globally, with projections of stabilization around this figure through 2027.
• Market forces remain influenced by regulatory, patent, and competitive factors.

FAQs

1. When did the key patents on aripiprazole expire?
The primary patent expired in 2015, leading to increased generic competition.

2. What are the main formulations of aripiprazole?
It is available as oral tablets, orally disintegrating tablets, and long-acting injectables.

3. Which companies manufacture generic aripiprazole?
Numerous generic manufacturers, including Teva, Mylan, and Sandoz, produce aripiprazole.

4. What are the leading markets for aripiprazole?
The U.S., European Union, China, and Japan account for the largest share of sales.

5. Are there any new indications or formulations in development?
Yes, ongoing research explores new formulations and off-label uses, potentially diversifying the market further.

---

References

[1] Food and Drug Administration. (2015). Approval notices.
[2] World Health Organization. (2019). Schizophrenia fact sheet.
[3] American Psychiatric Association. (2022). Practice guidelines.